Reduction in All-Cause Mortality with Fluticasone Furoate/Umeclidinium/Vilanterol in Patients with Chronic Obstructive Pulmonary Disease

Rationale: The IMPACT (Informing the Pathway of Chronic Obstructive Pulmonary Disease Treatment) trial demonstrated a significant reduction in all-cause mortality (ACM) risk with fluticasone furoate/umeclidinium/vilanterol (FF/UMEC/VI) versus UMEC/VI in patients with chronic obstructive pulmonary di...

Fuld beskrivelse

Na minha lista:
Bibliografiske detaljer
Udgivet i:Am J Respir Crit Care Med
Main Authors: Lipson, David A., Crim, Courtney, Criner, Gerard J., Day, Nicola C., Dransfield, Mark T., Halpin, David M. G., Han, MeiLan K., Jones, C. Elaine, Kilbride, Sally, Lange, Peter, Lomas, David A., Lettis, Sally, Manchester, Pamela, Martin, Neil, Midwinter, Dawn, Morris, Andrea, Pascoe, Steven J., Singh, Dave, Wise, Robert A.
Format: Artigo
Sprog:Inglês
Udgivet: American Thoracic Society 2020
Fag:
Original Articles
Online adgang:https://ncbi.nlm.nih.gov/pmc/articles/PMC7301738/
https://ncbi.nlm.nih.gov/pubmed/32162970
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1164/rccm.201911-2207OC
Tags: Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!

Lignende værker